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Purpose: A2B receptor agonists are studied as possible therapeutic tools for a variety of pathological conditions.
Unfortunately, medicinal chemistry efforts have led to the development of a limited number of potent agonists of
this receptor, in most cases with a low or no selectivity versus the other adenosine receptor subtypes. Among the
developed molecules, two structural families of compounds have been identified based on nucleoside and
non-nucleoside (pyridine) scaffolds. The aim of this work is to analyse the binding mode of these molecules at
3D models of the human A2B receptor to identify possible common interaction features and the key receptor
residues involved in ligand interaction.
Methods: The A2B receptor models are built by using two recently published crystal structures of the human A2A
receptor in complex with two different agonists. The developed models are used as targets for molecular docking
studies of nucleoside and non-nucleoside agonists. The generated docking conformations are subjected to energy
minimization and rescoring by using three different scoring functions. Further analysis of top-score conformations
are performed with a tool evaluating the interaction energy between the ligand and the binding site residues.
Results: Results suggest a set of common interaction points between the two structural families of agonists and
the receptor binding site, as evidenced by the superimposition of docking conformations and by analysis of
interaction energy with the receptor residues.
Conclusions: The obtained results show that there is a conserved pattern of interaction between the A2B receptor
and its agonists. These information and can provide useful data to support the design and the development of A2B
receptor agonists belonging to nucleoside or non-nucleoside structural families.
Keywords: Purinergic receptors; Adenosine receptors; Adenosine receptor agonists; Nucleosides; Purine derivatives;
Pyridine derivatives; Molecular modelling; Homology modelling; Molecular dockingBackground
Adenosine (Ado, Figure 1) is a naturally occurring
nucleoside that mediates numerous physiological and
pathological processes with effects on heart rate and
atrial contractility, vascular smooth muscle tone, release
of neurotransmitters, lipolysis, as well as renal, platelet,
and white blood cell functions (Cristalli and Volpini
2003). Ado activity is mediated by the activation of four
receptors that have been cloned (Robeva et al. 1996) and
classified as A1, A2A, A2B, and A3 adenosine receptor* Correspondence: rosaria.volpini@unicam.it
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in any medium, provided the original work is p(AR) subtypes (Fredholm et al. 2001) by considering the
respective coupling to second messengers. Furthermore,
ARs can be distinguished on the basis of their tissue
distribution and unique pharmacological profiles. These
membrane proteins, belonging to the G protein-coupled
receptor (GPCR) family, are hot targets due to their
therapeutic potential even though the lack of potent and
selective ligands for all subtypes still represents a weak-
ness for the attribution of specific biological activity and
for the development of therapeutic tools.
Among ARs, the A2BAR has been usually defined “low-
affinity AR” due to its lower affinity for Ado and for other
agonists respect to the other AR subtypes (Feoktistov andan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Molecular structure of Ado and NECA.
Table 1 Nucleoside A2BAR agonists analysed in this work
(see Additional file 1 for structural details)
cpd A1AR Ki, nM A2AAR Ki, nM A2BAR EC50, nM A3AR Ki, nM
1 0.67 1.8 920 1.4
2 221 9.3 3490 54.2
3 1050 1550 82 > 5000
4 2600 4100 175 > 5000
5 30.5 > 1000 42.6 107
6 2.1 2.0 220 0.75
The activity data are taken from Baraldi and co-workers (Baraldi et al. 2009).
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to activation of phospholipase C and adenylyl cyclase
through the coupling to the Gq and Gs proteins, respect-
ively. The A2BAR is widely expressed in the human body
and regulates several biological events at cardiovascular,
muscular, and central nervous systems, and also in cell
growth and during inflammation (Feoktistov and Biaggioni
1997). Hence, this receptor is of therapeutic interest for its
targeting in several conditions (Baraldi et al. 2009). In par-
ticular, the agonists of this receptor have been evaluated
for their cardioprotective effect, due to their reduced
bradycardic and hypotensive side effects respect to Ado
(Kuno et al. 2007; Philipp et al. 2006; Gao and Jacobson
2007; Eckle et al. 2007), for the treatment of coronary
artery disease (Hinschen et al. 2003; Ansari et al. 2007;
Kemp and Cocks 1999), and to promote angiogenesis
(Feoktistov et al. 2003; Feoktistov et al. 2004). Further
applications of A2BAR agonists have been explored on the
basis of the anti-inflammatory effect following the activa-
tion of this receptor, leading to the suggestion of the use
of these molecules in septic shock (Kreckler et al. 2006).
Even the use of A2BAR agonists for the treatment of renal
diseases, hypertension, cystic fibrosis, diabetes, and pul-
monary diseases associated with hyperplasia has been
considered (Volpini et al. 2003; Dubey et al. 2005).
Many efforts of medicinal chemistry have been focused
to the development of potent and selective AR agonists
and antagonists. In the case of the A2BAR, for several
years the nucleoside 4’-N-ethylcarboxamidoAdo (NECA,
Figure 1, EC50 = 140 nM) has represented and is still
used as reference agonist of this AR subtype, despite its
lack of subtype selectivity. Further agonists have been
developed by modifying the Ado and NECA structures
with the insertion of substituents at the 2- and N6-posi-
tions. The N6-substituents contain in most cases
substituted aromatic rings and polar groups directly
bound to 6-amine or to the aromatic function itself. A
series of NECA derivatives was developed by inserting at
the N6-position a large substituent similar to the one
present at the 8-position of xanthine derivatives thatbehave as potent A2BAR antagonists. Table 1 presents
some examples of nucleosides presenting agonist activity
at the A2BAR. The activity data are taken from a review
article by Baraldi and co-workers (Baraldi et al. 2009). In
general, the NECA derivatives present higher potency
respect to the corresponding Ado derivatives. In any
case, while the obtained potencies at the A2BAR are at
nanomolar level, the selectivity versus the other AR
subtypes is still low (Baraldi et al. 2009; Volpini et al.
2002; Lambertucci et al. 2003; Gao et al. 2004; Baraldi
et al. 2007a; Baraldi et al. 2007b).
A structural novelty on the development of A2BAR
agonists has been provided by the publication of a series
of pyridine derivatives presenting low nanomolar po-
tency at this AR subtype and in some cases remarkable
selectivity versus the other ARs. These compounds
present two cyano groups at the 3- and 5-positions, an
amino function at the 6-position, and two substituents at
the remaining 2- and 4-positions presenting various
profiles. In general, the 4-substituent contains an aromatic
group with possible substitutions at the 3- and 4- posi-
tions of the ring, while the 2-substituent contains a
thio-methyl spacer and a polar group (i.e. amide or 2-
imidazole) (Rosentreter et al. 2001; Rosentreter et al.
2003). Biological evaluation of these compounds has been
reported as functional assays at A2BAR expressed in
Chinese Hamster Ovary (CHO) cells and radioligand
binding assays at the remaining ARs (Beukers et al. 2004).
Among these derivatives, the compound 2-[(6-amino-3,5-
dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)
thio]acetamide (BAY 606583) has been evaluated for the
study of the role of the A2BAR in modulating the activity
of the immune system (van der Hoeven et al. 2011) and
for its possible use in case of heart ischemia (Eckle et al.
2007). Table 2 presents some examples of non-nucleoside
A2BAR agonists. The activity data are taken from a review
article by Baraldi and co-workers (Baraldi et al. 2009).
The aim of this work is to analyse the binding mode of
both nucleoside and non-nucleoside A2BAR agonists at
3D models of this AR subtype. The compounds presen-
ted in Tables 1 and 2 have been considered for this
analysis (see Additional file 1 for structural details). As a
Table 2 Non-nucleoside A2BAR agonists analysed in this
work (see Additional file 1 for structural details)
cpd A1AR Ki, nM A2AAR Ki, nM A2BAR EC50, nM A3AR Ki, nM
7 2.4 28 19 171
8 2.6 28 12 538
9 7.0 214 9 24
10 4.4 21 10 104
11 2.0 105 34 74
12 > 10000 > 10000 3 > 10000
The activity data are taken from Baraldi and co-workers (Baraldi et al. 2009).
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homology models of the human A2BAR by using as tem-
plates the crystal structures of the human A2AAR that is
the member of AR family presenting also the highest se-
quence conservation with the A2BAR. The binding mode
of ligands is then simulated by molecular docking tools,
followed by energy minimization and post-docking ana-
lysis. In this study, it is not possible to depict any correl-
ation between binding scores or interaction energies and
activity data, as the potencies of the compounds have
been measured as EC50 with functional studies and not
as Ki affinity with radioligand binding assays. Further-
more, the study provides an interpretation of the inter-
action features for both series of ligands at the A2BAR
but do not consider the interaction with the other AR
subtypes. Hence, the results of this study may provide
useful data for the design of A2BAR agonists but not for
the improvement of selectivity versus the other ARs.
Methods
All molecular modelling studies were performed on a
Core i7 CPU (PIV 2.20 GHZ) PC workstation. Homology
modelling, energy minimization, and docking studies were
carried out using Molecular Operating Environment
(MOE, version 2010.10) suite (Molecular Operating Envir-
onment). All ligand structures were optimized using
RHF/AM1 semiempirical calculations and the software
package MOPAC (Stewart 1990) implemented in MOE
was used for these calculations.
Homology modelling of the human A2BAR
Homology models of the human A2BAR were built using
the recently solved X-ray structures of the human
A2AAR in complex with Ado and UK-432097 as tem-
plates, both structures being retrieved from Protein Data
Bank (pdb code: 2YDO; 3.0-Å resolution (Lebon et al.
2011) and pdb code: 3QAK; 2.7-Å resolution (Xu et al.
2011), respectively). A multiple alignment of the AR pri-
mary sequences was built within MOE as a preliminary
step. For all A2BAR models, the boundaries identified
from the used X-ray crystal structure of A2AAR were
then applied for the corresponding sequences of thetransmembrane (TM) helices of the A2BAR. The missing
loop domains were built by the loop search method
implemented in MOE. Once the heavy atoms were mod-
elled, all hydrogen atoms were added, and the protein
coordinates were then minimized with MOE using the
AMBER99 force field (Cornell et al. 1995) until the Root
Mean Square (RMS) gradient of the potential energy
was less than 0.05 kJ mol-1 Å-1. Reliability and quality of
these models were checked using the Protein Geometry
Monitor application within MOE, which provides a
variety of stereochemical measurements for inspection
of the structural quality in a given protein, like backbone
bond lengths, angles and dihedrals, Ramachandran φ-ψ
dihedral plots, and quality of side chain rotamer and
non-bonded contact.
Molecular docking analysis
All compound structures were docked into the binding
site of the two A2BAR models using the MOE Dock tool.
This method is divided into a number of stages: Con-
formational Analysis of ligands. The algorithm generated
conformations from a single 3D conformation by con-
ducting a systematic search. In this way, all combina-
tions of angles were created for each ligand. Placement.
A collection of poses was generated from the pool of
ligand conformations using Triangle Matcher placement
method. Poses were generated by superposition of ligand
atom triplets and triplet points in the receptor binding
site. The receptor site points are alpha sphere centres
which represent locations of tight packing. At each
iteration a random conformation was selected, a random
triplet of ligand atoms and a random triplet of alpha
sphere centres were used to determine the pose. Scoring.
Poses generated by the placement methodology were
scored using two available methods implemented in
MOE, the London dG scoring function which estimates
the free energy of binding of the ligand from a given
pose, and Affinity dG scoring which estimates the
enthalpic contribution to the free energy of binding. The
top 30 poses for each ligand were output in a MOE
database.
Post docking analysis
The five top-score docking poses of each compound
were then subjected to AMBER99 force field energy
minimization until the RMS gradient of the potential
energy was less than 0.05 kJ mol-1 Å-1. Receptor residues
within 6 Å distance from the ligand were left free to
move, while the remaining receptor coordinates were
kept fixed. AMBER99 partial charges of receptor and
MOPAC output partial charges of ligands were utilized.
Once the compound-binding site energy minimization
was completed, receptor coordinates were fixed and a
second energy minimization stage was performed leaving
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(Halgren 1996a, b, c, d; Halgren and Nachbar 1996;
Halgren 1999a, b) was applied. For each compound, the
minimized docking poses were then rescored using
London dG and Affinity dG scoring functions and the
dock-pKi predictor. The latter tool allows the estimation
of the pKi for each ligand using the “scoring.svl” script
retrievable at the SVL exchange service (Chemical Com-
puting Group, Inc. SVL exchange: http://svl.chemcomp.
com). The algorithm is based on an empirical scoring
function consisting of a directional hydrogen-bonding
term, a directional hydrophobic interaction term, and an
entropic term (ligand rotatable bonds immobilized in
binding). For each compound and at each A2BAR model,
the top-score docking poses according to at least two
out of three scoring functions were selected for final
ligand-target interaction analysis.
The interactions between the ligands and the receptors
binding site were analysed by using the IF-E 6.0 tool
(Shadnia et al. 2009) retrievable at the SVL exchange
service. The program calculates and displays the atomic
and residue interaction forces as 3D vectors. It also
calculates the per-residue interaction energies, where nega-
tive and positive energy values (expressed as kcal mol-1)
are associated to favourable and unfavourable interactions,
respectively. A shell of residues contained within a 10 Å
distance from ligand were considered for this analysis.
Results and discussion
To simulate the binding mode of nucleoside and non-
nucleoside agonists at A2BAR and to compare the key
ligand-target interaction features of the two structural
families of compounds, a molecular docking analysis was
performed at homology models of the human A2BAR
developed by using two recently published crystal
structures of the agonist-bound A2AAR as templates
(pdb code: 2YDO; 3.0-Å resolution (Lebon et al. 2011)
and pdb code: 3QAK; 2.7-Å resolution (Xu et al. 2011),
in complex with Ado and UK-432097, respectively). The
availability of crystal structure the A2AAR allows to
improve the accuracy of AR homology models, due to
the high residue conservation in the primary sequences
of the AR subtypes (see Figure 2), sharing a sequence
identity of ~57% within the TM domains (Dal Ben et al.
2010b). The residues located within the seven TM
domains in the upper part of ARs, corresponding to the
ligand binding site, present a conservation (identity) at
about 71% (Costanzi et al. 2007). The obtained A2BAR
homology models were checked by using the Protein
Geometry Monitor application within MOE (Environment),
which provides a variety of stereochemical measurements
for inspection of the structural quality in a given protein,
such as backbone bond lengths, angles and dihedrals,
Ramachandran φ-ψ dihedral plots, and quality of side chainrotamer and non-bonded contact. The final A2BAR
models contain a disulfide bridge given by two cysteine
residues belonging to TM3 and extracellular loop (EL) 2
domains (Cys783.25 - where 3.25 indicates the residue
position within helix (Ballesteros and Weinstein 1995) -
and Cys171, respectively), in agreement with recent muta-
genesis studies (Schiedel et al. 2011) and as observed in
the case of recently reported modelling analyses on this
AR subtype (Sherbiny et al. 2009; Thimm et al. 2013;
Inamdar et al. 2013).
The A2BAR structures were then used as target for the
docking analysis of synthesised derivatives. All ligand
structures were optimized using RHF/AM1 semi-
empirical calculations and the software package MOPAC
implemented in MOE was utilized for these calculations
(Stewart 1990). The compounds were then docked into
the binding site of the A2BAR models by using the MOE
Dock tool. Top-score docking poses of each compound
were subjected to energy minimization; in this phase the
binding site residues within 6 Å proximity were left free
to move and to adapt their conformation to the ligand
moiety. Once this step was completed, a second minimi-
zation phase was performed keeping fixed the receptor
coordinates. The obtained ligand-target complexes were
then rescored using three available methods imple-
mented in MOE: the London dG scoring function that
estimates the free energy of binding of the ligand from a
given pose; the Affinity dG scoring tool that estimates
the enthalpic contribution to the free energy of binding;
the dock-pKi predictor that uses the MOE scoring.svl
script to estimate for each ligand a pKi value, which is
described by the H-bonds, transition metal interactions,
and hydrophobic interactions energy. For each com-
pound, the top-score docking pose at each A2BAR
model, according to at least two out of three scoring
functions, was selected for final ligand-target interaction
analysis.
The binding sites of the two developed A2BAR models
are very similar considering both receptor residues
orientation and pocket volumes. Slight differences are
still observable, due to diverse arrangements of some
residues detectable even at the two A2AAR crystal struc-
tures templates. For example, a glutamate residue
(Glu169 in the A2AAR) located within EL2 segment
makes a clear H-bond interaction with the N6-amino
group of Ado in the 2YDO crystal structure, while the
same residue is oriented in opposite direction when
observed within the 3QAK X-ray. This residue presents
different orientation even considering four previously
reported crystal structures of the A2AAR in complex
with ZM241385 antagonist (Jaakola et al. 2008; Dore
et al. 2011; Hino et al. 2012; Liu et al. 2012). Further-
more, a recent report on mutagenesis studies at the
A2AAR shows that the mutation of this residue does not
Figure 2 Sequence alignment of the four human AR subtypes. Transmembrane (TM), intracellular loop (IL), extracellular loop (EL), and C-
terminal (C-TERM) domains are indicated; * symbols indicate sequence identity in all the four subtypes; C letters indicate cysteine residues in-
volved in the disulfide bridge conserved among the four AR subtypes; letters coloured in yellow, cyan, and green indicate the A2BAR binding site
residues involved in ligand interaction (the colour indexing refers to the binding site subdivision described in Figure 5, see its legend for details).
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non-nucleoside agonists at this AR subtype (Lane et al.
2012). These data suggest that the interaction with this
residue is important but maybe not critical for the ligand
binding to the receptor. Analogously to what observed at
the 2YDO and 3QAK crystal structures, comparable
arrangements are respectively observed for the corre-
sponding residue (Glu174) at the two A2BAR models. In
the second case, this glutamate points towards the side
chain of Lys269 (EL3) making a strong polar interaction
with this amino acid. In any case, most of differences of
binding site residue arrangements are observed at EL
domains in peripheral regions of binding site and hence
have a marginal impact on the binding site size and
chemical-physical properties. As consequence, it is not a
surprise that the docking analysis of the synthesised
compounds at the two receptor models leads to analogue
results.
Considering the nucleoside agonists, the docking
conformations share a common motif, presenting theAdo/NECA derivatives located in the binding site simi-
larly to the co-crystallized nucleoside agonists. In detail,
adenine scaffold is positioned between TM3, TM6, and
TM7, with the 8- and 9-positions pointing towards the
core of the receptor, while the 2- and N6-substituents
are externally located (Figure 3A-B). The adenine plane
is stabilized by an aromatic stacking interaction with the
AR conserved phenylalanine residue in EL2 domain
(Phe173 in A2BAR), while the N
6-amino group and the
N7 atom interact through H-bonding with a conserved
asparagine (Asn2546.55 in A2BAR). The N
6-amino group
makes also H-bonding with Glu174 in the case of the
2YDO-based A2BAR model but not in the case of the
3QAK-based model, due to the different orientation of
the amino acid side chain. Considering again the 2YDO-
based A2BAR model, in the case of the presence of sub-
stituents at the N6-position of ligands (compounds 3–5),
a rearrangement of Glu174 side chain is observed during
post-docking minimization stage. The obtained confor-
mation of the amino acid is comparable to the one of
Figure 3 Results of docking studies. Docking conformations of nucleoside (compound 5: A-B; TM4 domain is partially hidden) and non-
nucleoside (compound 12: C-D) derivatives at the 2YDO-based A2BAR model and ligand-target interaction plots as computed by MOE software.
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and is able to make a polar interaction with Lys269. The
N6-substituents contain polar groups able to give polar
interactions with residues in their proximity. In
particular, compounds 3 and 4 contain a substituted
carbonyl-hydrazine at the 6-position, with the two polar
hydrogens of hydrazine group oppositely oriented and
pointing towards Asn2546.55 and Glu174 polar oxygens. In
the case of compound 5, the phenyl ring directly bound to
the N6-amine group causes a major rearrangement of
Glu174 side chain (2YDO-based A2BAR model) during
post-docking minimization step, leading to a conform-
ation highly similar to the same residue in 3QAK-based
model. The obtained minimized systems present in both
cases the Glu174- Lys269 polar interaction, with an
additional H-bonding between Glu174 and the polar
hydrogen atom of amide function within the N6-substitu-
ent. Further polar interaction is possible between the
carbonyl group of the same amide function of 5 and the
side chain of Asn266 (EL3). The 2-substituent (compounds
1, 2, 4–6) is located between TM1, TM2, TM7, and EL2with the position of phenyl ring (compounds 1, 2, 6)
roughly corresponding to the one occupied by the urea
group within the 2-substituent of co-crystallized UK-
432097 agonist. The ribose moiety is located into the TM
helices bundle, in a region between TM2, TM3, TM6, and
TM7 in close proximity to the conserved tryptophan
(Trp2476.48 in A2BAR) side chain. The ribose ring presents
the hydroxyl groups at the 2′- and 3′-position giving H-
bond interaction with A2BAR His280
7.43 and Ser2797.42
side chains, respectively. The Ado derivatives (1–2) present
in 4′-position a hydroxymethyl group located between
TM3 and TM6 and interacting with His2516.52 side chain,
while the 4′-ethylcarboxamido substituent of NECA
derivatives (3–6) is located in analogue position and gives
H-bond interaction with Thr893.36 and His2516.52.
Considering the non-nucleoside pyridine derivatives,
the lowest score and most populated family of docking
conformations shows the pyridine ring located in rough
correspondence to the adenine scaffold of nucleoside
agonists and forming a π-stacking interaction with
Phe173 (EL2, Figure 3C-D). Considering the positioning
Figure 4 Comparison of docking conformations. Superimposition
of docking conformations of nucleoside (compound 5) and
non-nucleoside (compound 12) derivatives at A2BAR at the
2YDO- and 3QAK-based A2BAR models (A and B, respectively). TM4
domain is partially hidden. The matching between functional groups
presenting analogue properties among the two molecules are
represented as pharmacophoric features (see text for details).
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the orientation of the pyridine agonists results somehow
comparable to the one obtained and schematically de-
scribed by Sherbiny and colleagues (Sherbiny et al. 2009)
but significantly different respect to the ones obtained in
more recent docking studies at the same AR subtype
(Thimm et al. 2013) and at the A2AAR (Lane et al.
2012). In detail, the interaction of the scaffold with the
A2BAR binding site is given as H-bonding between the
N1 atom and the 6-amino group of pyridines and the
amine and carbonyl groups of Asn2546.55 amide func-
tion, respectively. This double polar interaction is clearly
present only for some derivatives, due to the nature of
the 4-substituent that slightly modifies in some cases the
orientation of the scaffold. Analogously to the nucleoside
agonists, the amino group at the 6-position of pyridines
gives a H-bond interaction with Glu174 in the case of
the 2YDO-based A2BAR model, while in the case of the
3QAK-based model the side chain of the same residue
in some cases is not close enough to the ligand amino
group and hence not able to provide a clear H-bonding.
The thiomethylimidazole (7–11) and thioacetamide (12)
groups in 2-position are inserted between TM3, TM5,
and TM6 residues. In the case of compounds 7–11, the
H-bond donor function of imidazole is oriented towards
the oxygen atom of Thr893.36, while the acceptor feature
points towards the polar hydrogen of His2516.52. In the
case of compound 12, analogue interactions are given by
the amine and carbonyl functions of thioacetamide
group, respectively. The 3-cyano group is inserted
in a sub-cavity between Val853.32, Leu863.33, Thr893.36,
Ser2797.42, and His2807.43. No clear interaction with
binding site is given by this group, even though the pres-
ence of some space between this function and the polar
groups of Ser2797.42 and His2807.43 could allow the pres-
ence of a water molecule providing a sort of “bridge-
interaction” between ligand and binding site residues, as
observed, for example, in the case of a crystal structure
of A2AAR in complex with ZM241385 (Jaakola et al.
2008). The substituted aromatic group at the 4-position
is located in a sub-cavity given by TM1, TM2, TM3, and
TM7 residues, in close proximity to Tyr101.35, Ala642.61,
Ile672.64, Ser682.65, and Ile2767.39. Further residues in
proximity of this group are Val853.32 and Phe173. The
interaction is mainly hydrophobic, even if polar inter-
action could be given by the presence of a hydroxyl
function on the aromatic substituent (i.e. compounds 8
and 10). Finally, the 5-cyano group points towards the
extracellular environment and is located in proximity to
the couple of residues Glu174-Lys269.
To evaluate the possible common features for the
interaction with receptor binding site, the docking
conformations of nucleoside and non-nucleoside agonists
have been subjected to a comparative analysis performedand here presented considering two different points of
views. Firstly, a direct comparison can be made by the
superimposition of the representative docking conforma-
tions of one nucleoside and one non-nucleoside agonist,
with the aim of obtaining, if present, a sort of pharmaco-
phore description. In this sense, Figure 4 shows the super-
imposition of the docking conformations of compounds 5
and 12 (the most potent compounds from the two ligand
families) at the two A2BAR models. The results of the
superimposition are almost identical at the two receptor
models and highlight the presence of a series of common
interaction points that can be converted to pharmacopho-
ric features. In details, the 6-amino group of nucleosides
and pyridines are located in a similar position, providing a
H-bond donor feature able to interact with the H-bond
acceptor features given by the carbonyl group of
Asn2546.55 and, in some cases, by the carboxyl group of
Glu174 (EL2). Similarly, the N7 and N1 atoms of nucleo-
sides and pyridines, respectively, are almost superimposed
and represent a H-bond acceptor feature located in close
proximity with the donor function given by the amine
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more, the 4′-N-ethylcarboxamide function of the nucleo-
side derivative 5 presents the amide carbonyl group and
polar hydrogen in a nearly identical position to the
analogue functions of 2-thioacetamide group of com-
pound 12, suggesting the importance of the presence in
the ligand of a combination of H-bond acceptor and
donor features located in that sub-region of the binding
site. The carbonyl groups are located in close proximity to
a polar hydrogen of His2516.52, while the polar hydrogens
of the ligand amide groups are located near the polar
oxygen of Thr893.36. While the pyridine derivatives
present an amide function (compound 12) or an imidazole
ring (7–11) both able to provide the two pharmacophoric
features, in the case of nucleoside derivatives the two
functions can be present only in the case of NECA deriva-
tives (3–6), while the Ado analogues (1, 2) may fit only
one of the two polar features. This data is observable
already from the 2YDO and 3QAK crystal structures and
could in any case explain the general behaviour at ARs
according to which the Ado derivatives are generally less
potent respect to the corresponding NECA or MECA
(4′-N-methylcarboxamidoAdo) analogues. The dock-
ing position of the 3-cyano group of pyridines roughly
corresponds to the position of the nucleosides 2′-hydroxyl
function. As reported above, the cyano group is inserted
in a sub-cavity between Val853.32, Leu863.33, Thr893.36,
Ser2797.42, and His2807.43, with the presence of some
space between this function and the polar groups of
Ser2797.42 and His2807.43. In this sense, the possible pres-
ence of a water molecule providing a “bridge-interaction”
between ligand and binding site residues could suggest the
introduction of a sort of “polar group feature” correspond-
ing to the presence of the 2′-hydroxyl function of nucleo-
sides and the cyano group of pyridines. This polar group
could interact with Ser2797.42 and His2807.43 residues
directly (like in the case of nucleosides) or with the aid of
a bridging water molecule (in the case of pyridines). The
presence of a hydrophobic group at the 2-position of
nucleosides and at the 4-position of pyridines suggests the
presence of a large hydrophobic feature located within
TM1, TM2, and TM7 domains. This group seems critical
in particular for pyridine derivatives, as only some nucleo-
side agonists present a 2-hydrophobic substituent. Finally,
the position of the N1 atom of nucleosides is almost
coincident to the one of the nitrogen atom of the 5-cyano
group of pyridines, suggesting a possible H-bond acceptor
function in that position. However, it must be noted that
these atoms are oriented towards the extracellular envir-
onment and the H-bond donor counterpart could be
provided only by a special arrangement of Lys269 (EL3)
side chain. We underline that the use of a pharmacophore
model in this context is aimed only at helping for the
description of an interaction pattern that appearsconserved between nucleoside and non-nucleoside ago-
nists. For a development of a proper pharmacophore
model, a larger set of molecules and Ki affinity data should
be employed.
A second approach to compare the binding modes of
the different families of compounds at A2BAR consists in
evaluating the interaction of ligands with each binding
site residue, obtaining a set of data representing the
different effect of the A2BAR residues during the ligand-
target interaction. This analysis has been performed by
the use of the IF-E 6.0 (Shadnia et al. 2009) tool retriev-
able at the SVL exchange service. This method was
already used by our research group for the analysis of
ligand-target interaction for a series of potent A3AR
agonists (Dal Ben et al. 2010a). The script calculates and
displays atomic and residue interaction forces as 3D
vectors. It also calculates the per-residue interaction
energies (values in kcal mol-1), where negative and
positive energy values are associated to favourable and
unfavourable interactions, respectively. The script has
been applied to each compound at both A2BAR models.
To display the results, the binding site residues are
divided in three sections (Figure 5). The section 1 contains
residues belonging to TM1 (Tyr101.35 and Glu141.39),
TM2 (Ala642.61, Ile672.64, and Ser682.65), and TM7
(Ile2767.39, Ser2797.42, and His2807.43) domains, with the
insertion also of Val853.32, Phe173 (EL2), and Val2506.51.
These residues represent the receptor region interacting
with ligand adenine and pyridine scaffolds and with the
substituents at the 2-position of nucleosides and at the 3-
and 4-positions of pyridines. Residues interacting with
part of ribose atoms of nucleoside derivatives are also
included in this section. Figure 6 represents the obtained
results for section 1. The blue and red versions of the
plots represent the results obtained at the 2YDO- and
3QAK-A2BAR models, respectively. In agreement with
what appears from the superimposition of docking confor-
mations (see above), the effect of these residues is different
from nucleoside to non-nucleoside ligands as in the first
case the 2-substituent of nucleosides is present only in
some cases and presents different structural and chemical
profiles, while in the second case the 4-substituent of
pyridines is large and forming various interactions with
binding site residues. In detail, considering the nucleoside
derivatives 1–6, it clearly appears the effect of Phe173,
Ser2797.42, and His2807.43 in stabilizing the ligand-target
interaction. In particular, Phe173 is the key residue for
stabilizing the scaffold position within the binding site
through a π-stacking interaction, while Ser2797.42 and
His2807.43 are involved in polar interaction with 2′- and
3′-hydroxyl groups of nucleosides. The further contribu-
tion of Val2506.51 and Ile2767.39 for scaffold stabilization is
more evident at 2YDO-A2BAR model, while the role of
the carbonyl group of Ile672.64 backbone atoms in forming
Figure 5 Analysis of the role of binding site residues for the interaction with ligands. The binding site is divided in three sections
representing the TM1-TM2-TM7 and the TM3-TM5-TM6 regions of the cavity (cyan and green, respectively) and the entrance of the binding site
(yellow). TM4 domain is partially hidden.
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substituent of 1 and 6 is clearly evident at 3QAK-based
model. The latter residue forms also hydrophobic inter-
action with the alkynyl group of the nucleosides 1 and 6
(3QAK-based model). Considering the non-nucleoside
derivatives 7–12, results highlight the role of Val853.32,
Phe173, and Val2506.51 in stabilizing the ligand scaffold,
while the interaction with Ser2797.42 and His2807.43 is
lacking (see above). Tyr101.35 interacts with compound 12
in 3QAK-based model. Ile672.64 forms hydrophobic inter-
action with the 4-aromatic group of pyridines, while
Ala642.61 forms on the one hand a stable H-bond inter-
action with the para-hydroxyl group of the 4-aromatic
substituent of compound 8 (3QAK-based model), on the
other hand a hydrophobic interaction with 4-aromatic
group of 12. Comparing the results for this section with
previously reported data, it can be underlined that
Tyr101.35 showed to be critical for compound 12 activity
as evidenced from mutagenesis results (Thimm et al.
2013), while Ile672.64 and Ala642.61 were already reported
to possibly interact with the 4-substituent of pyridine
derivatives (Sherbiny et al. 2009). The effect of Ser2797.42
and His2807.43 is evident for nucleoside agonists but not
so well defined for non-nucleoside derivatives. In parti-
cular, the mutation of Ser2797.42 to alanine takes to a loss
of activity of nucleosides and, on the contrary, to an
improvement of non-nucleoside derivative EC50 data(Thimm et al. 2013). These results are confirmed at the
A2AAR (Lane et al. 2012). Our study confirms the effect
on nucleosides but does not highlight a direct interaction
with non-nucleoside derivatives. The histidine residue in
position 7.43 of ARs (His2807.43 in A2BAR) is reported to
be essential for receptor expression and function (Dal Ben
et al. 2010b; Thimm et al. 2013). Considering the
interaction of this residue in A2BAR with ligands, it has
been recently reported a molecular modelling study con-
sisting in the rebuilding of the three AR models other than
A2AAR and the use of the four AR 3D structures for a
molecular docking study of antagonists followed by
molecular dynamics analysis (Inamdar et al. 2013). Con-
sidering the results at the A2BAR, this study suggests a
possible direct contact of His2807.43 with a potent thiazole
antagonist. Further recent studies report that the mutation
of this histidine leads to a loss of interaction with ligands
(Thimm et al. 2013). As reported above, our modelling
study does not highlight a direct contact of His2807.43 with
non-nucleoside derivatives even if we cannot exclude that
an interaction of these ligands with this residue and
Ser2797.42 could be mediated by a water molecule.
The section 2 contains residues belonging to TM3
(Leu863.33, Thr893.36, Gln903.37, and Ile933.40), TM5
(Met1825.38, Asn1865.42, Cys1905.46, and Val1915.47), and
TM6 (Trp2476.48 and His2516.52). These residues are
involved in interaction with ribose group of nucleoside
Figure 6 Plot of interaction energies for residues belonging to the section 1 of the A2BAR binding site, calculated with the MOE IF-E
6.0 tool. Data are represented as kcal mol-1. The blue and red versions of the plots represent the results obtained at the 2YDO- and 3QAK-A2BAR
models, respectively. Plots A and B are referred to the interaction energies of nucleoside derivatives 1–6, while plots C and D are referred to the
non-nucleoside derivatives 7–12.
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substituent of non-nucleoside pyridine derivatives.
Figure 7 represents the obtained results for section 2,
again with blue and red versions corresponding to the
2YDO- and 3QAK-A2BAR models, respectively. The
effect of the receptor residues for the interaction with
ligands is comparable considering both nucleoside and
non-nucleoside agonists. Firstly, Leu863.33 and Met1825.38
form a hydrophobic interaction with the ribose group of
nucleosides and with the 2-substituent of pyridines.
Secondly, it appears evident the contribution of Thr893.36
and His2516.52, in accordance with the results of superim-
position experiments (see above). In particular, Thr893.36
provide a stabilizing effect for the polar hydrogen of
NECAs 5′-amide group from 3–6, of thiomethylimidazole
from 7–11, and of thioacetamide from 12. The effect of
this residue is largely reduced in the case of the two Ado
derivatives 1–2 that do not present a combination of
H-bond acceptor and donor features at the 5′-position.His2516.52 cooperates with Thr893.36 in providing a stabil-
izing effect for ligands. In the case of non-nucleoside
derivatives, it is interesting to notate the greater effect of
this residue for 12 respect to 7–11 at both A2BAR models,
suggesting a better interaction of His2516.52 for the amide
function respect to an imidazole ring. The effect of the
other residues of this section is not significant, with the
exception in some cases of Gln903.37 (polar interaction
with non-nucleoside derivatives in 3QAK-A2BAR model)
and Trp2476.48. In a previous study (Sherbiny et al. 2009),
Thr893.36 was suggested as interacting with 3-cyano sub-
stituent of 12 while His2516.52, Gln903.37, and Asn1865.42
were found as interacting (or in proximity) with the amide
group of the 2-substituent of the same compound.
Asn1865.42 appears as not directly interacting with the
compounds of this study. On the other hand, a mutagen-
esis study has evidenced that the mutation of this residue
to alanine leads to an increase of potency of both nucleo-
side and non-nucleoside derivatives (Thimm et al. 2013).
Figure 7 Plot of interaction energies for residues belonging to the section 2 of the A2BAR binding site, calculated with the MOE IF-E
6.0 tool. Data are represented as kcal mol-1. The blue and red versions of the plots represent the results obtained at the 2YDO- and 3QAK-A2BAR
models, respectively. Plots A and B are referred to the interaction energies of nucleoside derivatives 1–6, while plots C and D are referred to the
non-nucleoside derivatives 7–12.
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in the antagonist-bound A2AAR crystal structures but
present in the agonist-bound 3QAK X-ray data (in the
Ado- and NECA-bound A2AAR crystal structures the
Gln893.37 is mutated to alanine), hence these residues
could have a mechanistic role for the receptor function
and could be not necessarily interaction points for ligands
(Dal Ben et al. 2013).
The section 3 contains residues located close or at the
entrance of the binding site and belonging to EL2
(Leu172, Glu174, and Met179), TM6 (Val2536.54,
Asn2546.55, and Thr2576.58), EL3 (Asn266, Lys267,
Pro268, and Lys269), and TM7 (Met2727.35). These
residues are involved in interaction with the purine and
the pyridine scaffold, the C2– and N6-substituents of
nucleosides, and the 4-aromatic substituent, the 5-cyano
group, and the 6-amino function of pyridines. Even in
this case, the representation is divided in plots fornucleoside and non-nucleoside derivatives at the two
2YDO- and 3QAK-A2BAR models (Figure 8). The results
confirm the key role of Asn2546.55 for the interaction
with both families of ligands at both receptor models.
The importance of this residue for the interaction of
A2BAR with ligands has been highlighted even in re-
cently reported studies (Sherbiny et al. 2009; Inamdar
et al. 2013). Furthermore, it appears a relevant effect of
Glu174 for the interaction with nucleoside derivatives
1–6. The carboxyl function of this residue can interact
with the unsubstituted 6-amino group (1, 2, 6) or with
polar hydrogens present within the N6-substituent (3–5).
In the case of pyridine derivatives, the effect of this
residue is influenced by its conformation, as in the
2YDO-based A2BAR model its carboxyl group points
towards the 6-amino function of ligands providing H-
bond interaction, while in the case of 3QAK-based model
the side chain is oriented towards the extracellular
Figure 8 Plot of interaction energies for residues belonging to the section 3 of the A2BAR binding site, calculated with the MOE IF-E
6.0 tool. Data are represented as kcal mol-1. The blue and red versions of the plots represent the results obtained at the 2YDO- and 3QAK-A2BAR
models, respectively. Plots A and B are referred to the interaction energies of nucleoside derivatives 1–6, while plots C and D are referred to the
non-nucleoside derivatives 7–12.
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ation can be made for Lys269, whose side chain points to-
wards Glu174 and the N6-substituent of nucleoside
derivatives. In the case of compounds 1 and 6, the charged
amino group of this lysine interacts also with the hydroxyl
group within the 2-substituent. In the case of the non-
nucleoside derivatives, the Lys269 charged amino group is
located in proximity of 5-cyano function without forming
interaction with this group. The effect of the remaining
amino acids in this section seems not significant.
Conclusions
In conclusion, this study was aimed at simulating the
binding modes of nucleoside and non-nucleoside ago-
nists at two A2BAR homology models developed starting
from the X-ray structures of the A2AAR in complex with
Ado and UK-432097 as templates (pdb code: 2YDO and
3QAK, respectively). The docking conformations of
nucleoside derivatives were quite expected, while thenon-nucleoside derivatives demonstrated to bind to
these receptor models in a different way respect to pre-
viously reported studies at AR models. The generated
and minimized docking conformations were compared
by superimposition and by analysis of the interaction
with the binding site residues located in ligand proxim-
ity. Results showed that, beside the evident structural
differences among the two ligand families, the nucleo-
side and non-nucleoside derivatives bind to the A2BAR
through a series of conserved interaction points, sug-
gesting a sort of interaction pattern. The findings of this
analysis are in agreement with the results of the evaluation
of the role of binding site residues for the ligand-target
interaction and the conclusions of these studies are in
good agreement with mutagenesis and molecular model-
ling studies reported in the last years. Taken together,
these data could be helpful for the design of A2BAR ago-
nists belonging to nucleoside or non-nucleoside structural
families.
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Additional file 1: Table S1. Nucleoside A2BAR agonists analysed in
this work. The activity data are taken from Baraldi and co-workers
(Baraldi et al. 2009). Table S2. Non-nucleoside A2BAR agonists analysed
in this work. The activity data are taken from Baraldi and co-workers
(Baraldi et al. 2009).
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